Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaurab Chakrabarti

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Radiation Oncology (London, England)|July 16, 2015
Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancerGaurab Chakrabarti
Clinical Pharmacology : Advances and Applications|April 15, 2015
Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathwaysGaurab Chakrabarti, David E Gerber, David A Boothman
Plos One|May 10, 2017
Hydrogen peroxide inhibition of bicupin oxalate oxidaseJohn M Goodwin, Hassan Rana, Joan Ndungu, et al.
Biosensors & Bioelectronics|February 23, 2016
Using DNA devices to track anticancer drug activityDimithree Kahanda, Gaurab Chakrabarti, Marc A Mcwilliams, et al.
Molecular Cancer Research : MCR|November 11, 2015
Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLCBrian Madajewski, Michael A Boatman, Gaurab Chakrabarti, et al.
Urologic Oncology|November 17, 2012
What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-upAnna Buteau, Casey A Seideman, Robert S Svatek, et al.
Scientific Reports|November 26, 2015
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachoneGaurab Chakrabarti, Molly A Silvers, Mariya Ilcheva, et al.
Molecular Cancer Therapeutics|May 20, 2016
NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck CancerLong-Shan Li, Srilakshmi Reddy, Zhen-Hua Lin, et al.
Cancer & Metabolism|October 14, 2015
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneGaurab Chakrabarti, Zachary R Moore, Xiuquan Luo, et al.
Antioxidants & Redox Signaling|February 12, 2014
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancersLifen Cao, Long Shan Li, Christopher Spruell, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Radiation Oncology (London, England)|July 16, 2015
Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancerGaurab Chakrabarti
Clinical Pharmacology : Advances and Applications|April 15, 2015
Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathwaysGaurab Chakrabarti, David E Gerber, David A Boothman
Plos One|May 10, 2017
Hydrogen peroxide inhibition of bicupin oxalate oxidaseJohn M Goodwin, Hassan Rana, Joan Ndungu, et al.
Biosensors & Bioelectronics|February 23, 2016
Using DNA devices to track anticancer drug activityDimithree Kahanda, Gaurab Chakrabarti, Marc A Mcwilliams, et al.
Molecular Cancer Research : MCR|November 11, 2015
Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLCBrian Madajewski, Michael A Boatman, Gaurab Chakrabarti, et al.
Urologic Oncology|November 17, 2012
What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-upAnna Buteau, Casey A Seideman, Robert S Svatek, et al.
Scientific Reports|November 26, 2015
Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachoneGaurab Chakrabarti, Molly A Silvers, Mariya Ilcheva, et al.
Molecular Cancer Therapeutics|May 20, 2016
NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck CancerLong-Shan Li, Srilakshmi Reddy, Zhen-Hua Lin, et al.
Cancer & Metabolism|October 14, 2015
Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachoneGaurab Chakrabarti, Zachary R Moore, Xiuquan Luo, et al.
Antioxidants & Redox Signaling|February 12, 2014
Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancersLifen Cao, Long Shan Li, Christopher Spruell, et al.
Pageof 2